IP Verse

Heterocyclic Compound - EP3782986

EP3782986

TAKEDA PHARMACEUTICAL
Application Number
EP19774394A
Filing Date
Mar 28, 2019
Status
Granted And Under Opposition
Jun 7, 2024
Grant Date
Jul 10, 2024
External Links
Slate, Register, Google Patents

Bibliography

The patent EP3782986B1 was granted to Takeda Pharmaceutical on Jul 10, 2024 following the initial filing on Mar 28, 2019 under the application number EP19774394A . The current legal status of the patent is Granted And Under Opposition.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

DE CLERCQ & PARTNERSApr 10, 2025ADMISSIBLE

Patent Citations (16) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONJP2007091649
DESCRIPTIONUS2009143302
DESCRIPTIONWO2011012661
DESCRIPTIONWO2012066065
DESCRIPTIONWO2012101065
DESCRIPTIONWO2015058140
DESCRIPTIONWO2016058544
DESCRIPTIONWO9931072
INTERNATIONAL-SEARCH-REPORTJP2016533379
INTERNATIONAL-SEARCH-REPORTWO2016142855
INTERNATIONAL-SEARCH-REPORTWO2016193939
OPPOSITIONWO2006035967
OPPOSITIONWO2011012661
OPPOSITIONWO2015058140
OPPOSITIONWO2016058544
SEARCHEP1464335

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- "A Collection of Standard Experimental Procedures", L. F. TIETZETH. EICHER, Shinjikken Kagaku Kouza (Courses in Experimental Chemistry, John Wiley & Sons Inc, vol. I - VII-
DESCRIPTION- BAJRAMI I. et al., Cancer Res., (20140000), vol. 74, pages 287 - 297-
DESCRIPTION- BARTKOWIAK B. et al., Genes Dev., (20100000), vol. 24, pages 2303 - 2316-
DESCRIPTION- BLAZEK D. et al., Genes Dev., (20110000), vol. 25, pages 2158 - 2172-
DESCRIPTION- EKUMI KM. et al., Nucleic Acids Res., (20150000), vol. 43, pages 2575 - 2589-
DESCRIPTION- ITO M. et al., J. Med. Chem., (20180000), vol. 61, pages 7710 - 7728-
DESCRIPTION- "IYAKUHIN no KAIHATSU (Development of Pharmaceuticals", Design of Molecules, HIROKAWA SHOTEN, (19900000), vol. 7, pages 163 - 198-
DESCRIPTION- Strategic Applications of Named Reactions in Organic Synthesis, VCH Publishers Inc., (19890000), vol. 1, 14-
INTERNATIONAL-SEARCH-REPORT- REGISTRY, (20080608), Database accession no. 1026426-87-8, URL: STN [A] 1-10-
INTERNATIONAL-SEARCH-REPORT- REGISTRY, (20111204), Database accession no. 1348645-64-6, URL: STN [A] 1-10-
INTERNATIONAL-SEARCH-REPORT- ITO, M. et al., "Discovery of 3-Benzyl-1-(trans-4- ((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea derivatives as novel and selective cyclin- dependent kinase 12 (CDK12) inhibitors", J. Med. Chem., (20180801), vol. 61, no. 17, doi:doi:10.1021/acs.jmedchem.8b00683, pages 7710 - 7728, XP055618079 [PX] 1-10
OPPOSITION- D1 - compound 1-(3-Chloro-4-fluoro-phenyl)-1-[4-(4-dimethylamino-5-methyl-pyridin-2-ylamino)-cyclohexyl]-urea-
OPPOSITION- D7 - Expert Declaration by William J. Greenlee, Ph.D.-
OPPOSITION- Flores Natalia García, Fernández‐aroca Diego M., Garnés‐garcía Cristina, Domínguez‐calvo Andrés, Jiménez‐suárez Jaime, Sabater Sebastià, Fernández‐aroca Pablo, Andrés Ignacio, Cimas Francisco J., De Cárcer Guillermo, Belandia Borja, Palmero Ignacio, Huertas Pablo, Ruiz‐hidalgo María José, Sánchez‐prieto Ricardo, "The CDK12-BRCA1 signaling axis mediates dinaciclib-associated radiosensitivity through p53-mediated cellular senescence", Molecular Oncology, Elsevier, (20250401), vol. 19, no. 4, doi:10.1002/1878-0261.13773, ISSN 1574-7891, pages 1265 - 1280, XP093270909
OPPOSITION- Johnson Shawn F., Cruz Cristina, Greifenberg Ann Katrin, Dust Sofia, Stover Daniel G., Chi David, Primack Benjamin, Cao Shiliang, Bernhardy Andrea J., Coulson Rhiannon, Lazaro Jean-Bernard, Kochupurakkal Bose, Sun Heather, Unitt Christine, Moreau Lisa A., Sarosiek Kristopher A., Scaltriti Maurizio, Juric Dejan, Baselga José, Richardson Andrea L., Rodig Scott J., D’andrea Alan D., Balmaña Judith, Johnson Neil, Geyer Matthias, Serra Violeta, Lim Elgene, Shapiro Geoffrey I., "CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer", Cell Reports, Elsevier Inc, US, US , (20161101), vol. 17, no. 9, doi:10.1016/j.celrep.2016.10.077, ISSN 2211-1247, pages 2367 - 2381, XP055866968
OPPOSITION- Howard David, James David, Garcia-Parra Jezabel, Pan-Castillo Belen, Worthington Jenny, Williams Nicole, Coombes Zoe, Rees Sophie Colleen, Lutchman-Singh Kerryn, Francis Lewis W., Rees Paul, Margarit Lavinia, Conlan R. Steven, Gonzalez Deyarina, "Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer", Frontiers in Oncology, Frontiers Media S.A., vol. 12, doi:10.3389/fonc.2022.1014280, ISSN 2234-943X, XP093270906

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents